TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

TAVR and SAVR deliver similar outcomes for patients with low-flow, low-gradient aortic stenosis

Paravalvular leak was more common after TAVR, as one may expect, but that was the only notable difference between the two aortic valve replacement strategies. The study's authors did highlight the importance of additional research, including larger studies with longer follow-up periods.

Intravascular lithotripsy IVL carotid artery TAVR

A new use for IVL: helping cardiologists secure transcarotid access for TAVR

IVL can do more than help prep patients for PCI. In fact, one heart team used Shockwave Medical's IVL technology to secure access for a high-risk TAVR patient.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Answering key follow-up questions after the FDA approved TAVR in asymptomatic patients

The approval of certain TAVR valves to be used in asymptomatic patients is expected to make a significant impact on patient care going forward. 

artificial intelligence heart AI

AI predicts LBBB risk in TAVR patients prior to treatment

The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.

cardiologists heart doctors

Cardiologists share late-breaking TAVR data on first day of SCAI 2025

New TAVR data on SAPT vs. DAPT and prosthesis-patient mismatch among women were some of the many highlights of the conference's opening day.

Philippe Genereux, MD, director of the structural heart program at Morristown Medical Center, principal investigator of the late-breaking EARLY TAVR trial, presented new data at ACC 2025 showing intervening earlier on patients with asymptomatic severe aortic stenosis leads to better outcomes.

Latest EARLY TAVR data suggest it is time to update industry guidelines

Philippe Genereux, MD, principal investigator of EARLY TAVR, presented new data at ACC.25 showing intervening early on crossover patients with asymptomatic severe aortic stenosis led to better outcomes and a reduced stroke rate. 

Sapien 3 Ultra Resilia TAVR valves

A victory for early treatment: FDA approves first TAVR valves for asymptomatic severe aortic stenosis

The FDA has approved the balloon-expandable Sapien 3 TAVR platform from Edwards Lifesciences for treating asymptomatic severe aortic stenosis. This is the first time the agency has approved any TAVR technology to be used in asymptomatic patients. 

Michael J. Reardon, MD, the Allison Family Distinguished Chair in Cardiovascular Research and a professor of medicine at the DeBakey Heart and Vascular Center, Houston Methodist Hospital, explains the late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting. The data show positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).

Self-expanding TAVR valves deliver outcomes and durability comparable to surgery after 5 years

Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways. 

Displaying 9 - 16 of 489
Design by Adaptive Theme